High expression of HER3 is associated with a decreased survival in gastric cancer

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7843-7849

  Hayashi, Mikiko ^a   Inokuchi, Mikito ^a   Takagi, Yoko ^a   Yamada, Hiroyuki ^a   Kojima, Kazuyuki ^a   Kumagai, Jiro ^a   Kawano, Tatsuyuki ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GASTRECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR GROWTH; ADENOCARCINOMA; BIOSYNTHESIS; GENE EXPRESSION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-3; STOMACH NEOPLASMS;

EID: 59449104266     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1064     Document Type: Article

References (57)

1. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241:27-39.
2. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20.
3. Cutsem EV, MoiseyenkoVM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006;24:4991 -7.
4. Koizumi W, Narahara H, HaraT, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21.
5. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19: 3159-67.
6. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004;306:1506-7.
7. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341 -54.
8. YonemuraY, Sugiyama K, Fushida S, et al. Tissue status of epidermal growth factor and its receptor as an indicator of poor prognosis in patients with gastric cancer. Anal Cell Pathol 1991;3:343-50.
9. HironoY, Tsugawa K, Fushida S, et al. Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology 1995;52:182-8.
10. Anzai H, Kitadai Y, Bucana CD, Sanchez R, Omoto R, Fidler IJ. Expression of metastasis -related genes in surgical specimens of human gastric cancer can predict disease recurrence. Eur J Cancer1998;34:558-65.
11. Koullias GJ, Kouraklis GP, Raftopoulos IS, Davaris PS, Paradopoulos SA, Golematis BC. Increased estrogen receptor and epidermal growth factor receptor gene product co-expression in surgically resected gastric adenocarcinomas. J Surg Oncol 1996;63: 166-71.
12. Yonemura Y, Ninomiya I, Ohoyama S, et al. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivityforc-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer1991;67:2914-8.
13. Lee EY, Cibull ML, Strodel WE, Haley JV. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. Arch Pathol Lab Med1994;118:235-9.
14. Brien TP, Depowski PL, Sheehan CE, Ross JS, Mckenna BJ. Prognostic factors in gastric cancer. Mod Pathol 1998;11:870-7.
15. Tsugawa K, Fushida S, Yonemura Y. Amplification of the c-erbB-2 gene in gastric carcinoma: correlation with survival. Oncology1993;50:418-25.
16. Nakajima M, Sawada H,Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer1999;85:1894-902.
17. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated proteasesystems. JClin Oncol 2000;18:2201 -9.
18. García I, Vizoso F, Martín A, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003;10:234-41.
19. Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003;22:258(A1036).
20. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-7.
21. Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.JClinOncol2002;20:3106-13.
22. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl JMed 2001;344:783-92.
23. SanidasEE,FilipeMI,LinehanJ,etal. Expressionof the c-erbB-3 gene product in gastric cancer. Int J Cancer1993;54:935-40.
24. Slesak B, Harlozinska A, Porebska I, et al. Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. Anticancer Res1998;18: 2727-32.
25. Kataoka H, Joh T, Kasugai K, et al. Expression of mRNA for heregulin and its receptor, ErbB-3 and ErbB-4, in human upper gastrointestinal mucosa. Life Sci 1998;63:553-64.
26. Witton CJ, Reeves JR, Going JJ, CookeTG, Bartlett JMS. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200: 290-7.
27. JacobsTW, Gown AM,Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/ neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. JClin Oncol1999;17:1983-7.
28. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy thantamoxi- fen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19: 3808-16.
29. Tanner B, Hasenclever D, Stern K, et al. ErbB-3 pre- dictssurvival inovariancancer. JClinOncol 2006;24: 4317-23.
30. Kapitanovic S, Radosevic S,Slade N, et al. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 2000;126:205-11.
31. Bieche I, Onody P,Tozlu S, Driouch K,Vidaud M, Lindereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003; 106:758-65.
32. Naidu R, Yadav M, Nair S, Kutty MK. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998;78:1385-90.
33. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. BrJ Cancer 2004;91:1532-42.
34. Lemoine NR, Barnes DM, Hollywood DP, et al. Expression of the ERBB3 gene product in breast cancer. BrJ Cancer1992;66:1116-21.
35. Travis A, Pinder SE, Robertson JF, et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 1996;74:229-33.
36. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 2008;15:1193-201.
37. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 2007;31:493-9.
38. Suo Z, Risberg B, Kalsson MG, et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002;196:17-25.
39. Sassen A, RochonJ, Wild P, et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008; 10:R2.
40. Aubele M, Auer G,Walch AK, et al. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 2007;96:801-7.
41. Quinn CM, Ostrowski JL, Lane SA, Loney DP, Teasdale J, Benson FA. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 1994; 25:247-52.
42. Kountourakis P, Pavlakis K, Psyrri A, et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006;6:46.
43. Lee JC,Wang ST, Chow NH,Yang HB. Investigation of the prognostic value of coexpressed erb B family members for the survival of colorectal cancer patients aftercurative surgery. Eur J Cancer2002;38:1065-71.
44. Lee CH, Huntsman DG, Cheang MC, et al. Assessment ofHer-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 2005;24:147-52.
45. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBOJ1997;16:1647-55.
46. HolbroT, Beerli RR, Maurer F,KoziczakM,Barbas CF III, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003;100:8933 -8.
47. Maurer CA, Friess H, Kretschmann B, et al. In- creasedexpression oferbB3 in colorectal cancer isas- sociated with concomitant increase in the level of erbB2. Hum Pathol 1998;29:771-7.
48. Jain S, Filipe MI, GullickWJ, Linehan J, Morris RW. c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohisto- chemical study on archival material. Int ancer1991; 48:668-71.
49. Tateishi M,TodaT, MinamisonoY, Nagasaki S. Clini- copathological significance of c-erbB-2 protein ex- pression in human gastric carcinoma. J Surg Oncol 1992;49:209-12.
50. Ohguri T, SatoY, Koizumi W, Saigenji K, KameyaT. An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator? Int J Cancer1993;53:75-9.
51. SasanoH,DateF,ImataniA,AsakiS,NaguraH.Dou- ble immunostaining for c-erbB-2 and p53 in human stomach cancercells. Hum Pathol 1993;24:584-9.
52. Gü JrelS, Dolar E, YerciO, et al. The relationship between c-erb B-2 oncogene expression and clinicopathological factors in gastric cancer. J Int Med Res 1999;27:74-8.
53. Noguchi H, Sakamoto C,Wada K, et al: Expression of heregulin α, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells. Gastroenterology1999;117:1119-27.
54. Iida A, Hirose K, Arai M, Ymaguchi A, Nakagawara G. Relationships among the expression of epidermal growth factor receptor, proliferating cell nuclear antigen labeling index, and lymph nodemetastasis in gastric cancer. Oncology1995;52:189-95.
55. Ekberg T, Nestor M, Engstrom M, et al. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. IntJ Oncol 2005;26:1177 -85.
56. Van der Horst EH, Murgia M,Treder M, et al: Anti- HER-3 mAbs inhibit HER-3- mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. IntJ Cancer 2005;115:519 -27.
57. KuniiK, DavisL, GorensteinJ, et al.FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008; 68:2340-8.